GRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary

GRI Bio

14/08/2026 15:08

GRI Bio Inc GRI.OQ reported a quarterly adjusted loss of 91 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-36.68.  The mean expectation of two analysts for the quarter was for a loss of $1.19 per share. Wall Street expected results to range from $-1.24 to $-1.15 per share.
Reported revenue was zero​; analysts expected zero. 
GRI Bio Inc's reported EPS for the quarter was a loss of 91 cents​.
The company reported a quarterly loss of $1.64 million.
GRI Bio Inc shares had held steady so far this quarter and lost 74.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 11.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for GRI Bio Inc is $156.00, about 98.9% above its last closing price of $1.77
This summary was machine generated from LSEG data August 14 at 02:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.19
-0.91
Beat
Mar. 31 2026 
-0.90
-1.61
Missed
Dec. 31 2025 
-29.26
-1.17 hundred
Missed
Sep. 30 2025 
-26.04
-35.84
Missed